We've found
3,276
archived clinical trials in
Pancreatic Cancer
We've found
3,276
archived clinical trials in
Pancreatic Cancer
Surgery in Treating Patients With Resectable Pancreatic Neoplasms
Immunologic Studies of Tumors of the Pancreas
Status: Archived
Surgery in Treating Patients With Resectable Pancreatic Neoplasms
Updated: 1/1/1970
Immunologic Studies of Tumors of the Pancreas
Status: Archived
Updated: 1/1/1970
Phase I Study Combining Suicide Gene Therapy With Chemoradiotherapy in the Treatment of Non-Metastatic Pancreatic Adenocarcinoma
Phase I Study Combining Replication-Competent Adenovirus-Mediated Suicide Gene Therapy With Chemoradiotherapy for the Treatment of Non-Metastatic Pancreatic Adenocarcinoma
Status: Archived
Phase I Study Combining Suicide Gene Therapy With Chemoradiotherapy in the Treatment of Non-Metastatic Pancreatic Adenocarcinoma
Updated: 1/1/1970
Phase I Study Combining Replication-Competent Adenovirus-Mediated Suicide Gene Therapy With Chemoradiotherapy for the Treatment of Non-Metastatic Pancreatic Adenocarcinoma
Status: Archived
Updated: 1/1/1970
A Trial of Chemo & Radiation Therapy for Pancreatic Cancer
A Phase II Trial of Cetuximab, Gemcitabine, 5-Fuorouracil and Radiation Therapy in Locally Advanced Non-metastatic Pancreatic Adenocarcinoma
Status: Archived
A Trial of Chemo & Radiation Therapy for Pancreatic Cancer
Updated: 1/1/1970
A Phase II Trial of Cetuximab, Gemcitabine, 5-Fuorouracil and Radiation Therapy in Locally Advanced Non-metastatic Pancreatic Adenocarcinoma
Status: Archived
Updated: 1/1/1970
Abdominal Exploration Without Incisions
Diagnostic Transluminal Endoscopic Peritoneoscopy
Status: Archived
Abdominal Exploration Without Incisions
Updated: 1/1/1970
Diagnostic Transluminal Endoscopic Peritoneoscopy
Status: Archived
Updated: 1/1/1970
Phase I/II Trial of Radiation, Avastin and Tarceva for Pancreatic Adenocarcinoma
A Phase I/II Trial of Radiation, Avastin and Tarceva for Resectable or Locally Advanced Pancreatic Adenocarcinoma
Status: Archived
Phase I/II Trial of Radiation, Avastin and Tarceva for Pancreatic Adenocarcinoma
Updated: 1/1/1970
A Phase I/II Trial of Radiation, Avastin and Tarceva for Resectable or Locally Advanced Pancreatic Adenocarcinoma
Status: Archived
Updated: 1/1/1970
IDO Inhibitor Study for Relapsed or Refractory Solid Tumors
A Phase I Study of 1-methyl-D-tryptophan (D-1MT) in Patients With Relapsed or Refractory Solid Tumors
Status: Archived
IDO Inhibitor Study for Relapsed or Refractory Solid Tumors
Updated: 1/1/1970
A Phase I Study of 1-methyl-D-tryptophan (D-1MT) in Patients With Relapsed or Refractory Solid Tumors
Status: Archived
Updated: 1/1/1970
A Study of 7 Day's of Erlotinib Before Surgery, Followed by After Surgery Erlotinib-gemcitabine in Patients With Pancreatic Cancer
UAB 0808, A Phase II Study of Short-course Preoperative Erlotinib Followed by Post-operative Erlotinib-gemcitabine in Patients With Resectable Pancreatic Adenocarcinoma
Status: Archived
A Study of 7 Day's of Erlotinib Before Surgery, Followed by After Surgery Erlotinib-gemcitabine in Patients With Pancreatic Cancer
Updated: 1/1/1970
UAB 0808, A Phase II Study of Short-course Preoperative Erlotinib Followed by Post-operative Erlotinib-gemcitabine in Patients With Resectable Pancreatic Adenocarcinoma
Status: Archived
Updated: 1/1/1970
Intensity-Modulated Radiation Therapy and Gemcitabine in Treating Patients With Locally Advanced Pancreatic Cancer
Phase I/II Radiotherapy Dose Escalation Study in Locally Advanced Pancreatic Cancer, Using a Simultaneous Intensity Modulated Boost With Concurrent Gemcitabine
Status: Archived
Intensity-Modulated Radiation Therapy and Gemcitabine in Treating Patients With Locally Advanced Pancreatic Cancer
Updated: 1/1/1970
Phase I/II Radiotherapy Dose Escalation Study in Locally Advanced Pancreatic Cancer, Using a Simultaneous Intensity Modulated Boost With Concurrent Gemcitabine
Status: Archived
Updated: 1/1/1970
Biomarkers in Predicting Response to Treatment in Patients Who Have Undergone Surgery for Pancreatic Cancer
Developing Predictive Markers of Therapeutic Response in Pancreatic Cancer
Status: Archived
Biomarkers in Predicting Response to Treatment in Patients Who Have Undergone Surgery for Pancreatic Cancer
Updated: 1/1/1970
Developing Predictive Markers of Therapeutic Response in Pancreatic Cancer
Status: Archived
Updated: 1/1/1970
Biomarkers in Predicting Response to Treatment in Patients Who Have Undergone Surgery for Pancreatic Cancer
Developing Predictive Markers of Therapeutic Response in Pancreatic Cancer
Status: Archived
Biomarkers in Predicting Response to Treatment in Patients Who Have Undergone Surgery for Pancreatic Cancer
Updated: 1/1/1970
Developing Predictive Markers of Therapeutic Response in Pancreatic Cancer
Status: Archived
Updated: 1/1/1970
Biomarkers in Predicting Response to Treatment in Patients Who Have Undergone Surgery for Pancreatic Cancer
Developing Predictive Markers of Therapeutic Response in Pancreatic Cancer
Status: Archived
Biomarkers in Predicting Response to Treatment in Patients Who Have Undergone Surgery for Pancreatic Cancer
Updated: 1/1/1970
Developing Predictive Markers of Therapeutic Response in Pancreatic Cancer
Status: Archived
Updated: 1/1/1970
A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients
A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients
Status: Archived
A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients
Updated: 1/1/1970
A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients
Status: Archived
Updated: 1/1/1970
A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients
A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients
Status: Archived
A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients
Updated: 1/1/1970
A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients
Status: Archived
Updated: 1/1/1970
Vorinostat in Combination With Radiation Therapy and Infusional Fluorouracil (5-FU) in Patients With Locally Advanced Adenocarcinoma of the Pancreas
Phase 1/2 Study of Vorinostat in Combination With Radiation Therapy and Infusional 5-FU in Patients With Locally Advanced Adenocarcinoma of the Pancreas
Status: Archived
Vorinostat in Combination With Radiation Therapy and Infusional Fluorouracil (5-FU) in Patients With Locally Advanced Adenocarcinoma of the Pancreas
Updated: 1/1/1970
Phase 1/2 Study of Vorinostat in Combination With Radiation Therapy and Infusional 5-FU in Patients With Locally Advanced Adenocarcinoma of the Pancreas
Status: Archived
Updated: 1/1/1970
Vorinostat in Combination With Radiation Therapy and Infusional Fluorouracil (5-FU) in Patients With Locally Advanced Adenocarcinoma of the Pancreas
Phase 1/2 Study of Vorinostat in Combination With Radiation Therapy and Infusional 5-FU in Patients With Locally Advanced Adenocarcinoma of the Pancreas
Status: Archived
Vorinostat in Combination With Radiation Therapy and Infusional Fluorouracil (5-FU) in Patients With Locally Advanced Adenocarcinoma of the Pancreas
Updated: 1/1/1970
Phase 1/2 Study of Vorinostat in Combination With Radiation Therapy and Infusional 5-FU in Patients With Locally Advanced Adenocarcinoma of the Pancreas
Status: Archived
Updated: 1/1/1970
Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride
A Phase I/II Study of Sorafenib and Everolimus in Patients With Advanced Solid Tumors and Gemcitabine-Refractory Metastatic Pancreatic Cancer
Status: Archived
Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride
Updated: 1/1/1970
A Phase I/II Study of Sorafenib and Everolimus in Patients With Advanced Solid Tumors and Gemcitabine-Refractory Metastatic Pancreatic Cancer
Status: Archived
Updated: 1/1/1970
Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride
A Phase I/II Study of Sorafenib and Everolimus in Patients With Advanced Solid Tumors and Gemcitabine-Refractory Metastatic Pancreatic Cancer
Status: Archived
Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride
Updated: 1/1/1970
A Phase I/II Study of Sorafenib and Everolimus in Patients With Advanced Solid Tumors and Gemcitabine-Refractory Metastatic Pancreatic Cancer
Status: Archived
Updated: 1/1/1970
Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine
Phase II Study of Coagulation Factor VIIa Inhibitor PCI-27483 in Pancreatic Cancer Patients Receiving Treatment With Gemcitabine, Part A
Status: Archived
Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine
Updated: 1/1/1970
Phase II Study of Coagulation Factor VIIa Inhibitor PCI-27483 in Pancreatic Cancer Patients Receiving Treatment With Gemcitabine, Part A
Status: Archived
Updated: 1/1/1970
Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine
Phase II Study of Coagulation Factor VIIa Inhibitor PCI-27483 in Pancreatic Cancer Patients Receiving Treatment With Gemcitabine, Part A
Status: Archived
Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine
Updated: 1/1/1970
Phase II Study of Coagulation Factor VIIa Inhibitor PCI-27483 in Pancreatic Cancer Patients Receiving Treatment With Gemcitabine, Part A
Status: Archived
Updated: 1/1/1970
Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine
Phase II Study of Coagulation Factor VIIa Inhibitor PCI-27483 in Pancreatic Cancer Patients Receiving Treatment With Gemcitabine, Part A
Status: Archived
Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine
Updated: 1/1/1970
Phase II Study of Coagulation Factor VIIa Inhibitor PCI-27483 in Pancreatic Cancer Patients Receiving Treatment With Gemcitabine, Part A
Status: Archived
Updated: 1/1/1970
Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine
Phase II Study of Coagulation Factor VIIa Inhibitor PCI-27483 in Pancreatic Cancer Patients Receiving Treatment With Gemcitabine, Part A
Status: Archived
Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine
Updated: 1/1/1970
Phase II Study of Coagulation Factor VIIa Inhibitor PCI-27483 in Pancreatic Cancer Patients Receiving Treatment With Gemcitabine, Part A
Status: Archived
Updated: 1/1/1970
Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine
Phase II Study of Coagulation Factor VIIa Inhibitor PCI-27483 in Pancreatic Cancer Patients Receiving Treatment With Gemcitabine, Part A
Status: Archived
Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine
Updated: 1/1/1970
Phase II Study of Coagulation Factor VIIa Inhibitor PCI-27483 in Pancreatic Cancer Patients Receiving Treatment With Gemcitabine, Part A
Status: Archived
Updated: 1/1/1970
Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine
Phase II Study of Coagulation Factor VIIa Inhibitor PCI-27483 in Pancreatic Cancer Patients Receiving Treatment With Gemcitabine, Part A
Status: Archived
Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine
Updated: 1/1/1970
Phase II Study of Coagulation Factor VIIa Inhibitor PCI-27483 in Pancreatic Cancer Patients Receiving Treatment With Gemcitabine, Part A
Status: Archived
Updated: 1/1/1970
Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine
Phase II Study of Coagulation Factor VIIa Inhibitor PCI-27483 in Pancreatic Cancer Patients Receiving Treatment With Gemcitabine, Part A
Status: Archived
Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine
Updated: 1/1/1970
Phase II Study of Coagulation Factor VIIa Inhibitor PCI-27483 in Pancreatic Cancer Patients Receiving Treatment With Gemcitabine, Part A
Status: Archived
Updated: 1/1/1970
Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine
Phase II Study of Coagulation Factor VIIa Inhibitor PCI-27483 in Pancreatic Cancer Patients Receiving Treatment With Gemcitabine, Part A
Status: Archived
Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine
Updated: 1/1/1970
Phase II Study of Coagulation Factor VIIa Inhibitor PCI-27483 in Pancreatic Cancer Patients Receiving Treatment With Gemcitabine, Part A
Status: Archived
Updated: 1/1/1970
Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine
Phase II Study of Coagulation Factor VIIa Inhibitor PCI-27483 in Pancreatic Cancer Patients Receiving Treatment With Gemcitabine, Part A
Status: Archived
Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine
Updated: 1/1/1970
Phase II Study of Coagulation Factor VIIa Inhibitor PCI-27483 in Pancreatic Cancer Patients Receiving Treatment With Gemcitabine, Part A
Status: Archived
Updated: 1/1/1970
Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine
Phase II Study of Coagulation Factor VIIa Inhibitor PCI-27483 in Pancreatic Cancer Patients Receiving Treatment With Gemcitabine, Part A
Status: Archived
Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine
Updated: 1/1/1970
Phase II Study of Coagulation Factor VIIa Inhibitor PCI-27483 in Pancreatic Cancer Patients Receiving Treatment With Gemcitabine, Part A
Status: Archived
Updated: 1/1/1970
Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine
Phase II Study of Coagulation Factor VIIa Inhibitor PCI-27483 in Pancreatic Cancer Patients Receiving Treatment With Gemcitabine, Part A
Status: Archived
Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine
Updated: 1/1/1970
Phase II Study of Coagulation Factor VIIa Inhibitor PCI-27483 in Pancreatic Cancer Patients Receiving Treatment With Gemcitabine, Part A
Status: Archived
Updated: 1/1/1970
Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine
Phase II Study of Coagulation Factor VIIa Inhibitor PCI-27483 in Pancreatic Cancer Patients Receiving Treatment With Gemcitabine, Part A
Status: Archived
Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine
Updated: 1/1/1970
Phase II Study of Coagulation Factor VIIa Inhibitor PCI-27483 in Pancreatic Cancer Patients Receiving Treatment With Gemcitabine, Part A
Status: Archived
Updated: 1/1/1970
Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine
Phase II Study of Coagulation Factor VIIa Inhibitor PCI-27483 in Pancreatic Cancer Patients Receiving Treatment With Gemcitabine, Part A
Status: Archived
Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine
Updated: 1/1/1970
Phase II Study of Coagulation Factor VIIa Inhibitor PCI-27483 in Pancreatic Cancer Patients Receiving Treatment With Gemcitabine, Part A
Status: Archived
Updated: 1/1/1970
Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine
Phase II Study of Coagulation Factor VIIa Inhibitor PCI-27483 in Pancreatic Cancer Patients Receiving Treatment With Gemcitabine, Part A
Status: Archived
Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine
Updated: 1/1/1970
Phase II Study of Coagulation Factor VIIa Inhibitor PCI-27483 in Pancreatic Cancer Patients Receiving Treatment With Gemcitabine, Part A
Status: Archived
Updated: 1/1/1970
Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine
Phase II Study of Coagulation Factor VIIa Inhibitor PCI-27483 in Pancreatic Cancer Patients Receiving Treatment With Gemcitabine, Part A
Status: Archived
Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine
Updated: 1/1/1970
Phase II Study of Coagulation Factor VIIa Inhibitor PCI-27483 in Pancreatic Cancer Patients Receiving Treatment With Gemcitabine, Part A
Status: Archived
Updated: 1/1/1970
A Study Evaluating Gemcitabine Plus Bosutinib for Patients With Resected Pancreatic Cancer
A Study Evaluating Safety and Efficacy of Gemcitabine Plus Bosutinib for Patients With Resected Pancreatic Adenocarcinoma
Status: Archived
A Study Evaluating Gemcitabine Plus Bosutinib for Patients With Resected Pancreatic Cancer
Updated: 1/1/1970
A Study Evaluating Safety and Efficacy of Gemcitabine Plus Bosutinib for Patients With Resected Pancreatic Adenocarcinoma
Status: Archived
Updated: 1/1/1970
A Study Evaluating Gemcitabine Plus Bosutinib for Patients With Resected Pancreatic Cancer
A Study Evaluating Safety and Efficacy of Gemcitabine Plus Bosutinib for Patients With Resected Pancreatic Adenocarcinoma
Status: Archived
A Study Evaluating Gemcitabine Plus Bosutinib for Patients With Resected Pancreatic Cancer
Updated: 1/1/1970
A Study Evaluating Safety and Efficacy of Gemcitabine Plus Bosutinib for Patients With Resected Pancreatic Adenocarcinoma
Status: Archived
Updated: 1/1/1970
Secretin-enhanced Magnetic Resonance Cholangiopancreatography (S-MRCP) and Pancreatic Function Following Surgery
MRCP With Secretin Stimulation for the Evaluation of Pancreatic Endocrine and Exocrine Function Following Surgical Resection for Pancreatic Adenocarcinoma
Status: Archived
Secretin-enhanced Magnetic Resonance Cholangiopancreatography (S-MRCP) and Pancreatic Function Following Surgery
Updated: 1/1/1970
MRCP With Secretin Stimulation for the Evaluation of Pancreatic Endocrine and Exocrine Function Following Surgical Resection for Pancreatic Adenocarcinoma
Status: Archived
Updated: 1/1/1970
Secretin-Stimulated Magnetic Resonance Cholangiopancreatography (S-MRCP) as Screening in Familial Pancreatic Cancer (CA) Patients
Secretin-Stimulated MRCP as an Early Screening Modality for Pancreatic Ductal Abnormalities in Patients at High Risk for Pancreatic Adenocarcinoma: A Pilot Study
Status: Archived
Secretin-Stimulated Magnetic Resonance Cholangiopancreatography (S-MRCP) as Screening in Familial Pancreatic Cancer (CA) Patients
Updated: 1/1/1970
Secretin-Stimulated MRCP as an Early Screening Modality for Pancreatic Ductal Abnormalities in Patients at High Risk for Pancreatic Adenocarcinoma: A Pilot Study
Status: Archived
Updated: 1/1/1970
Comparison of Secretin-enhanced Magnetic Resonance Cholangiopancreatography (S-MRCP) to Endoscopic Pancreatic Function Test (ePFT) in Diagnosing Pancreatic Exocrine Insufficiency
Comparison of Secretin Enhanced MRCP to Endoscopic Pancreatic Function Testing in Diagnosing Exocrine Insufficiency in Patients Who Have Undergone Pancreas Cancer Resection
Status: Archived
Comparison of Secretin-enhanced Magnetic Resonance Cholangiopancreatography (S-MRCP) to Endoscopic Pancreatic Function Test (ePFT) in Diagnosing Pancreatic Exocrine Insufficiency
Updated: 1/1/1970
Comparison of Secretin Enhanced MRCP to Endoscopic Pancreatic Function Testing in Diagnosing Exocrine Insufficiency in Patients Who Have Undergone Pancreas Cancer Resection
Status: Archived
Updated: 1/1/1970
A Phase II Study of Pertuzumab and Erlotinib for Refractory Pancreatic Adenocarcinoma
A Phase II Study of Pertuzumab and Erlotinib for Refractory Pancreatic Adenocarcinoma
Status: Archived
A Phase II Study of Pertuzumab and Erlotinib for Refractory Pancreatic Adenocarcinoma
Updated: 1/1/1970
A Phase II Study of Pertuzumab and Erlotinib for Refractory Pancreatic Adenocarcinoma
Status: Archived
Updated: 1/1/1970
A Pilot Study to Evaluate the Efficacy and Safety of Neoadjuvant Chemoradiotherapy With Capecitabine, . . .
A Phase II Pilot Study to Evaluate the Efficacy and Safety of Neoadjuvant Chemoradiotherapy With Capecitabine, Panitumumab and External Beam Radiation, in Patients With Localized, Non-Metastatic Pancreatic Adenocarcinoma
Status: Archived
A Pilot Study to Evaluate the Efficacy and Safety of Neoadjuvant Chemoradiotherapy With Capecitabine, . . .
Updated: 1/1/1970
A Phase II Pilot Study to Evaluate the Efficacy and Safety of Neoadjuvant Chemoradiotherapy With Capecitabine, Panitumumab and External Beam Radiation, in Patients With Localized, Non-Metastatic Pancreatic Adenocarcinoma
Status: Archived
Updated: 1/1/1970
Nab-paclitaxel (Abraxane), Gemcitabine, and Capecitabine (Xeloda) for Pancreatic Adenocarcinoma
A Phase I Study of Nab-paclitaxel (Abraxane), Gemcitabine, and Capecitabine (Xeloda) (AGX) in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
Status: Archived
Nab-paclitaxel (Abraxane), Gemcitabine, and Capecitabine (Xeloda) for Pancreatic Adenocarcinoma
Updated: 1/1/1970
A Phase I Study of Nab-paclitaxel (Abraxane), Gemcitabine, and Capecitabine (Xeloda) (AGX) in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
Status: Archived
Updated: 1/1/1970
Nab-paclitaxel (Abraxane), Gemcitabine, and Capecitabine (Xeloda) for Pancreatic Adenocarcinoma
A Phase I Study of Nab-paclitaxel (Abraxane), Gemcitabine, and Capecitabine (Xeloda) (AGX) in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
Status: Archived
Nab-paclitaxel (Abraxane), Gemcitabine, and Capecitabine (Xeloda) for Pancreatic Adenocarcinoma
Updated: 1/1/1970
A Phase I Study of Nab-paclitaxel (Abraxane), Gemcitabine, and Capecitabine (Xeloda) (AGX) in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
Status: Archived
Updated: 1/1/1970
Efficacy and Safety Study of LE-DT to Treat Locally Advanced or Metastatic Pancreatic Cancer
A Multicenter, Open-Label, Phase II Study of LE-DT for Efficacy and Safety in Patients With Locally Advanced or Metastatic Pancreatic Cancer
Status: Archived
Efficacy and Safety Study of LE-DT to Treat Locally Advanced or Metastatic Pancreatic Cancer
Updated: 1/1/1970
A Multicenter, Open-Label, Phase II Study of LE-DT for Efficacy and Safety in Patients With Locally Advanced or Metastatic Pancreatic Cancer
Status: Archived
Updated: 1/1/1970
RO4929097 Before Surgery in Treating Patients With Pancreatic Cancer
.A Neoadjuvant Pharmacodynamic Study Of RO4929097 (RO) in Pancreas Cancer
Status: Archived
RO4929097 Before Surgery in Treating Patients With Pancreatic Cancer
Updated: 1/1/1970
.A Neoadjuvant Pharmacodynamic Study Of RO4929097 (RO) in Pancreas Cancer
Status: Archived
Updated: 1/1/1970
RO4929097 Before Surgery in Treating Patients With Pancreatic Cancer
.A Neoadjuvant Pharmacodynamic Study Of RO4929097 (RO) in Pancreas Cancer
Status: Archived
RO4929097 Before Surgery in Treating Patients With Pancreatic Cancer
Updated: 1/1/1970
.A Neoadjuvant Pharmacodynamic Study Of RO4929097 (RO) in Pancreas Cancer
Status: Archived
Updated: 1/1/1970
RO4929097 Before Surgery in Treating Patients With Pancreatic Cancer
.A Neoadjuvant Pharmacodynamic Study Of RO4929097 (RO) in Pancreas Cancer
Status: Archived
RO4929097 Before Surgery in Treating Patients With Pancreatic Cancer
Updated: 1/1/1970
.A Neoadjuvant Pharmacodynamic Study Of RO4929097 (RO) in Pancreas Cancer
Status: Archived
Updated: 1/1/1970
RO4929097 Before Surgery in Treating Patients With Pancreatic Cancer
.A Neoadjuvant Pharmacodynamic Study Of RO4929097 (RO) in Pancreas Cancer
Status: Archived
RO4929097 Before Surgery in Treating Patients With Pancreatic Cancer
Updated: 1/1/1970
.A Neoadjuvant Pharmacodynamic Study Of RO4929097 (RO) in Pancreas Cancer
Status: Archived
Updated: 1/1/1970
RO4929097 Before Surgery in Treating Patients With Pancreatic Cancer
.A Neoadjuvant Pharmacodynamic Study Of RO4929097 (RO) in Pancreas Cancer
Status: Archived
RO4929097 Before Surgery in Treating Patients With Pancreatic Cancer
Updated: 1/1/1970
.A Neoadjuvant Pharmacodynamic Study Of RO4929097 (RO) in Pancreas Cancer
Status: Archived
Updated: 1/1/1970
RO4929097 Before Surgery in Treating Patients With Pancreatic Cancer
.A Neoadjuvant Pharmacodynamic Study Of RO4929097 (RO) in Pancreas Cancer
Status: Archived
RO4929097 Before Surgery in Treating Patients With Pancreatic Cancer
Updated: 1/1/1970
.A Neoadjuvant Pharmacodynamic Study Of RO4929097 (RO) in Pancreas Cancer
Status: Archived
Updated: 1/1/1970
RO4929097 Before Surgery in Treating Patients With Pancreatic Cancer
.A Neoadjuvant Pharmacodynamic Study Of RO4929097 (RO) in Pancreas Cancer
Status: Archived
RO4929097 Before Surgery in Treating Patients With Pancreatic Cancer
Updated: 1/1/1970
.A Neoadjuvant Pharmacodynamic Study Of RO4929097 (RO) in Pancreas Cancer
Status: Archived
Updated: 1/1/1970
RO4929097 Before Surgery in Treating Patients With Pancreatic Cancer
.A Neoadjuvant Pharmacodynamic Study Of RO4929097 (RO) in Pancreas Cancer
Status: Archived
RO4929097 Before Surgery in Treating Patients With Pancreatic Cancer
Updated: 1/1/1970
.A Neoadjuvant Pharmacodynamic Study Of RO4929097 (RO) in Pancreas Cancer
Status: Archived
Updated: 1/1/1970